Abstract
The non-ionic surfactants Cremophor EL (CrEL) and Tween 80,both used as formulation vehicles of many (anticancer) agentsincluding paclitaxel and docetaxel, are not physiologicalinert compounds. We describe their biological properties,especially the toxic side effects, and their pharmacologicalproperties, such as modulation of P-glycoprotein activity. Indetail, we discuss their influence on the disposition of thesolubilized drugs, with focus on CrEL and paclitaxel, and ofconcomitantly administered drugs. The ability of thesurfactants to form micelles in aqueous solution as well asbiological fluids (e.g. plasma) appears to be of greatimportance with respect to the pharmacokinetic behavior of theformulated drugs. Due to drug entrapment in the micelles,plasma concentrations and clearance of free drug changesignificant leading to alteration in pharmacodynamiccharacteristics. We conclude with some perspectives related tofurther investigation and development of alternative methodsof administration.
Similar content being viewed by others
References
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. VI: The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325–2327, 1971
Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 15: 141–147, 1993
Dorr RT: Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 28: S11–S14, 1994
Hoffmann H: Polyoxyäthylenglycerol triricinoleat 35 DAC 1979. Pharm Zeit 129: 1730–1733, 1984
Goldspiel BR: Guidelines for administration. In: McGuire WP, Rowinsky EK (eds) Paclitaxel in Cancer Treatment. Marcel Dekker Inc, New York, 1995, pp 175–186
Onetto N, Dougan M, Hellmann S, Gustafson N, Burroughs J, Florczyk A, Canetta R, Rozenweig M: Safety profile. In: McGuire WP, Rowinsky EK (eds) Paclitaxel in Cancer Treatment. Marcel Dekker, New York, 1995, pp 21–149
Hayes FA, Abromowitch, Green AA: Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies. Cancer Treat Rep 69: 439–441, 1985
Howrie DL, Ptachcinski RJ, Griffith P, Hardesty RJ, Rosenthal JT, Burckart GJ, Venkataramanan R: Anaphylactoid reactions associated with parenteral cyclosporine use: possible role of Cremophor EL. Drug Intell Clin Pharm 19: 425–427, 1985
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla R, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263–1268, 1990
Nannan Panday VR, Huizing MT, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418–427, 1997
Onetto N, Canetta R, Winograd B, Catane R, Dougan M, Grechko J, Burroughs J, Rozencweig M: Overview of Taxol safety. J Natl Cancer Inst Monogr 15: 131–139, 1993
Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, Van Der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabárbara P, Onetto N, Winograd B, Canetta R: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654–2666, 1994
Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED: Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97: 42–46, 1996
Watkins J, Ward AM, Appleyard TN: Adverse reactions to intravenous anaesthetic induction agents. Br Med J 2: 1084–1085, 1977
Hüttel MS, Schou Olesen A, Stoffersen E: Complementmediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth 52: 77–79, 1980
Szebeni J, Muggia FM, Alving CR: Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90: 300–306, 1998
Van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A: Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. Anti-Cancer Drugs 11: 315–324, 2000
Lorenz WM, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A: Histamine release in dogs by Cremophor EL and its derivatives: oxyethelated oleic acid is the most effective constituent. Agents Actions 7: 63–67, 1977
Bergh M, Magnusson K, Nilsson JL, Karlberg AT: Contact allergenic activity of Tween 80 before and after air exposure. Contact Dermatitis 37: 9–18, 1997
Lesser GJ, Grossman SA, Eller S, Rowinsky6EK: The distribution of systemically administered [3H]-paclitaxel in rats: a quantitiative autoradiographic study. Cancer Chemother Pharmacol 37: 173–178, 1995
De Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RAF: Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med 317: 861–886, 1987
Sparreboom A, Van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O: Limited oral bioavailability and active epithelia excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 4: 2031–2035, 1997
Meerum-Terwogt JM, Malingré MM, Beijnen JH, Ten Bokkel Huinink WW, Rosing H, Koopman FJ, Van Tellingen O, Swart M, Schellens JHM: Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 5: 3379–3384, 1999
Evans WC: Drugs containing acids, alcohols and esters. In: Pharmacognosy, 13th ed. Baillière Tindall, London, 1989, p 333
Windebank AJ, Blexrud MD, Groen PC: Potential neurotoxicity of the solvent vehicle for cyclosporine. J Pharmacol Exp Ther 268: 1051–1056, 1994
Brat DJ, Windebank AJ, Brimijoin S: Emusifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 261:803–810, 1992
Podratz JL, Windebank AJ: Dialyzer associated neurotoxicity due to a change in fatty acid structure. Trans Am Soc Neurochem 24: 229, 1993
Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495–505, 1994
Roman ID, Monte MJ, Esteller A, Jimenez R: Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, CrEL. Transplant 48: 554–558, 1989
Chan FK, Shaffer EA: Cholestatic effects of cyclosporin in the rat. Transplant 63: 1574–1578, 1997
Luke DR, Kasiske BL, Matzke GR, Awni WM, Keane WF: Effects of cyclosporine on the isolated perfused rat kidney. Transplant 43: 795–801, 1987
Besarab A, Jarrell BE, Hirsch S, Carabasi RA, Cressman MD, Green P: Use of the isolated perfused kidney model to assess the acute pharmacologic effets of cyclosporine and its vehicle, cremophor EL. Transplant 44: 195–201, 1957
Abraham JS, Bentley FR, Garrison RN, Cryer HM: The in-fluence of the cyclosporine vehicle, Cremophor EL, on renal microvascular blood flow in the rat. Transplant 52: 101–105, 1991
Rothenberg ML: Taxol, Taxotere and other new taxanes. Curr Opin Invest Drugs 2: 1269–1277, 1993
Drori S, Eytan GD, Assaraf YG: Potentiation of anticancerdrug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability. Eur J Biochem 228: 1020–1029, 1995
Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D: Measurement of CrEL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685–1690, 1993
Sparreboom A, Van Tellingen O, Huizing MT, Nooijen WJ, Beijnen JH: Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. J Chromatogr B 681: 355–362, 1996
Sparreboom A, Loos WJ, Verweij J, De Vos AI, Van der Burg MEL, Stoter G, Nooter K: Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. Anal Biochem 255: 171–175, 1998
Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A: Linearized colorimetric assay for Cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. Anal Biochem 261: 198–202, 1998
Van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ, Sparreboom A: Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res 5: 2918–2924, 1999
Kunkel M, Meyer T, Bohler J, Keller E, Frahm AW: Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids. J Pharm Biomed Anal 21: 911–922, 1999
Oszi Z, Petho G: Quantitative determination of polysorbate 20 in nasal pharmaceutical preparations by high-performance liquid chromatography. J Pharm Biomed Anal 18: 715–720, 1998
Smullin CF, Wetterau FP, Olanski VL: The determination of polysorbate 60 in foods.J Am Oil Chem Soc 48: 18–20, 1971
Smullin CF: Quantitative determination of polysorbate 60 in non-standard salad dressings. J Assoc Off Anal Chem 61: 506–507, 1978
McKean DL, Pesce AJ: Determination of polysorbate in ascites fluid from a premature patient. J Anal Toxicol 9: 174–176, 1985
Kato H, Nagai Y, Yamamoto K, Sakabe Y: Determination of polysorbates in foods by colorimetry with confirmation by infrared spectrophotometry, thin-layer chromatography, and gas-chromatography. J Assoc Off Anal Chem 72: 27–29, 1989
McKean DL, Pesce AJ, Koo W: Analysis of polysorbate and its polyoxyethylated metabolite. Anal Blochem 161: 348–351, 1987
Meerum Terwogt JM, Van Tellingen O, Nannan Panday VR, Huizing MT, Schellens JHM, Ten Bokkel Huinink WW, Boschma MUS, Giaccone G, Veenhof CHN, Beijnen JH: Cremophor EL pharmacokinetics in a Phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients. Anticancer Drugs 11: 687–694, 2000
Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG, Bishop JF: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88: 1297–1301, 1996
Sparreboom A, Verweij J, van der Burg MEL, Loos WJ, Brouwer E, Viganó L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L: Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin Cancer Res 4: 1937–1942, 1998
Nannan Panday VR, Huizing MT, Van Tellingen O, Hakvoort RA, Willemse PHB, De Graeff A, Vermorken JB, Beijnen JH: Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving taxol. In: Clinical Pharmacology of Paclitaxel and Platinum Compounds. Academic Thesis, Utrecht University, 1999, pp 109–120
Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A: Disposition of [G-3H]paclitaxel and Cremophor EL in a patient severely impaired renal function. Drug Metab Dispos 27: 1300–1305, 1999
Nelson MF, Poulas TA, Gongwer LE, Kischman JC: Preparation of carbon-14-labeled polyoxyethylene (20) sorbitan monolaurate and their metabolitic fate in rats. J Food Sci 31: 253–258, 1966
Culver PJ, Wilcox CS, Jones CM, Ross RS: Intermediary metabolism of certain polyoxyethylene derivatives in man. I. Recovery of the polyoxyethylene moiety from urine and feces following ingestion of polyoxyethylene (20) sorbitan monooletate and of polyoxyethylene (40) monostearate.J Pharmacol Exp Ther 103: 377–381, 1951
Elworthy PH, Treon JF: Physiological activity of nonionic surfactants. In: Schick M (ed) Nonionic Surfactants, Surfactant Science Series, Vol 1. Marcel Dekker, New York, 1967, pp 923–970
Azmin MN, Stuart JFB, Florence AT: The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80. Cancer Chemother Pharmacol 14: 238–242, 1985
Treon JF, Gongwer LE, Nelson MF, Kischman JC: Physiology and metabolic patterns of non-ionic surfactants In: Paquot P (ed) Chemistry, Physics and Application of Surface-active Substances, vol 3. Gordon and Breach, London, 1967, p 381
Azmin MN, Stuart JFB, Calman KC, Florence AT: Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice. Cancer Chemother Pharmacol 9: 161–164, 1982
Sparreboom A, Van Tellingen O, Nooijen W, Beijnen JH: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56: 2112–2115, 1996
Sparreboom A, Van Zuyien L, Brouwer E, Loos6WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454–1457, 1999
Kessel D, Woodburn K, Decker D, Sykes E: Fractionation of Cremophor EL delineates components responsible for plasma lipoprotein alterations and multidrug resistance reversal. Oncol Res 7: 207–212, 1995
Sykes E, Woodburn K, Decker D, Kessel D: Effect of Cremophor EL on distribution of Taxol to serum lipoproteins. Br J Cancer 70: 401–404, 1994
Knemeyer I, Wientjes MG, Au JL-S: Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44: 241–248, 1999
Van Tellingen O, Huizing MT, Nannan Panday VR, Schellens JHM, Nooijen WJ, Beijnen JH: Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81: 330–335, 1999
Kearns CM: Pharmacokinetics of the taxanes. Pharmacotherapy 17: 105S–109S, 1997
Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmcokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 13: 180–190, 1995
Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N: Clinical pharmacokineties and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599–606, 1995
Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP: Phase I trial of Taxol given as a 24-hour infusion every 21 days, responses observed in metastatic melanoma. J Clin Oncol 5: 1232–1239, 1987
Sparreboom A, Verweij J, Van Zuylen L, Karlsson MO: A pharmacokinetic model for micellar encapsulation of paclitaxel in Cremophor EL. (Abstract). Proc Am Assoc Cancer Res 41: 522, 2000
Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH: Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 7: 78–86, 1996
Ellis AG, Webster LK: Inhibiton of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 43: 13–18, 1999
Kessel D: Properties of Cremophor EL micelles probed by fluorescence. Photochem Photobiol 56: 447–451, 1992
Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906–1915, 1997
Webster LK, Cosson EJ, Stokes KH, Millward MJ: Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73: 522–524, 1996
Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JIF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM: Phase I trial of Cremophor EL with bolus doxorubicin. Clin Cancer Res 4: 2321–2329, 1998
Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M: Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 10: 391–395, 1999
Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a Phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713–2721, 1996
Duska LR, Penson R, Supko JG, Finkelstein DM, Makastorsis T, Gallagher J, Borden K, Goodman A, Fuller AF, Nikrui N, Seiden MV: A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colonystimulating factor for relapsed epithelial ovarian cancer. Clin Cancer Res 5: 1299–1305, 1999
Ellis AG, Crinis NA, Webster LK: Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80. Cancer Chemother Pharmacol38: 81–87, 1996
Woodburn K, Chang CK, Lee S, Henderson B, Kessel D: Biodistribution and PIDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem Photobiol 60: 154–159, 1994
Kurlansky PA, Sadeghi AM, Michler RE, Coppey LJ, Re LP, Thomas WG, Smith CR, Reemtsma K, Rose EA: Role of the carrier solution in cyclosporine pharmacokinetics in the baboon. J Heart Transplant 5: 312–316, 1986
Kay NH, Uppington J, Sear JW, Douglas EJ, Cockshott ID: Pharmacokinetics of propofol (Diprivan) as an induction agent. Postgrad Med J 61: 55–57, 1985
Harrison SD, Cusic AM, McAfee SM: Tween 80 increases plasma adriamycin concentrations in mice by an apparent reduction of plasma volume. Eur J Cancer 17: 387–389, 1981
Cummings J, Forrest GJ, Cunningham D, Gilchrist NL, Soukop M: Influence of polysorbate 80 (Tween 80) and etoposide (VP–16–213) on the pharmacokinetics and urinary excretion of Adriamycin and its metabolies in cancer patients. Cancer Chemother Pharmacol 17: 80–84, 1986
Bourgeois H, Gruia G, Dieras V, Kalla S, Giaccetti S, Cvitkovic E, Aussel JP, Azli N, Riva A, Poullart P, Misser JL: Docetaxel in combination with doxorubicin as first line chemotherapy of metastatic breast cancer: a Phase I dose finding study. (Abstract) Proc Am Assoc Clin Oncol 15: 148, 1996
Sandstrom M, Simonsen LE, Freijs A, Karlsson MO: The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother Pharmacol 44: 469–474, 1999
Eposito M, Venturini M, Vannozzi MO, Tolino G, Lunardi G, Garrone O, Angiolini C, Viale M, Bergaglio M, Del Mastro L, Rosso R: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetic of epirubicin in breast cancer patients. J Clin Oncol 17: 1132–1138, 1999
D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A: Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Sem Oncol 25: 16–20, 1998
Gannt L, Crochman N, Dyniewicz JM: Effect of a detergent on gastro-intestinal absorption of a steroid. Lancet 1: 486, 1961
Hikal AH: Effect of polysorbate 80 on the apparent partition coefficient of drugs on their intestinal absorption in the rat: II. Phenobarbital. Int J Pharm 7: 205–210, 1981
Katzemi K, Arita T, Muranishi S: Absorption and excretion of drugs: XXVI. Effect of non-ionic surface-active agents on rectal absorption of sulphonamides. Chem Pharm Bull 13: 976–980, 1965
Masters JR, McDermott BJ, Jenkins WE, Fenwick E, Shah PJ, Mundy AR, Loadman PM, Bibby MC: Thiotepa pharmacokinetics during intravesical chemotherapy and the in-fluence of Tween 80. Cancer Chemother Pharmacol 25: 267–273, 1990
Woodcock DM, Jefferson S, Linsenmeyer ME, Crowther PJ, Chojnowski GM, Williams B, Bertoncello I: Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 50: 4199–4203, 1990
Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH: Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62–68, 1992
Friche E, Jensen PB, Sehested M, Demant EF, Nissen NN: The solvents Cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor. Cancer Commun 2: 297–303, 1990
Schuurhuis GJ, Broxterman HJ, Pinedo HM, Van Heijningen THM, Van Kalker CK, Vermorken JB, Spoelstra EC, Lankelma J: The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer 62: 591–594, 1990
Chervinsky DS, Brecher ML, Hoelcle MJ: Cremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res 13: 93–96, 1993
Hwang M, Ahn C-H, Pine PS, Yin JJ, Hrycyna CA, Licht T, Aszalos A: Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells. Int J Cancer 65: 389–397, 1996
Sinicrope FA, Dudeja PK, Bissonnette BM, Safa AR, Brasitus TA:Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles. J Biol Chem 267: 24995–25002, 1992
Dudeja PK, Anderson KM, Harris JS, Buckingham L, Coon JS: Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 319: 309–315, 1995
Webster LK, Linsenmeyer ME, Rischin D, Urch ME, Woodcock DM, Millward MJ: Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer Chemother Pharmacol 39: 557–560, 1997
Sparreboom A, Van Asperen J, Van Tellingen O, Smit JW, Schinkel AH, Nooijen WJ, Beijnen JH: Pharmacokinetics of paclitaxel in mdr1a P-glycoprotein deficient mice after intravenous and oral administration (Abstract).Ann Oncol 7: 91, 1996
Slater L, Sweet P, Wetzel M, Stupecky M, Osann K: Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 19: 543–548, 1995
Watanabe T, Nakayama Y, Naito M, Oh-hara T, Itoh Y, Tsuruo T: Cremophor EL reversed multidrug resistance in vitro but not in tumor-bearing mouse models. Anticancer Drugs 7: 825–832, 1996
Nooter K, Sonneveld P: Clinical relevance of P-glycoprotein expression in hematological malignancies. Leuk Res 18: 233–243, 1994
Ross DD, Wooten PJ, Tong Y, Cornblatt B, Levy C, Sridhara R, Lee EJ, Schiffer CA: Synergistic reversal of multidrug resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL. Blood 83: 1337–1347, 1995
Solomon MB, Meenem B, Heavey C, Paietta E: Differential modulation of P-glycoprotein, the multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells. Blood 86: 4385–4386, 1995
Tsujino I, Yamazaki T, Matsutani M, Sawada U, Horie T: Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells. Cancer Chemother Pharmacol 43: 29–34, 1999
Hacker M, Koeferl M, Hong CB: Cremophor and Emulphor induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs. Res Commun Chem Pathol Pharmacol 31: 119–128, 1981
Bertoncello I, Kriegler AB, Woodcock DM, Williams B, Barber L, Nilsson SK: Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. Int J Radiat Biol 67: 57–64, 1995
Ennis M, Lorenz W, Gerland W, Heise J: Isolation of mast cells from rabbit lung and liver: comparison of histamine release induced by the hypnotics Althesin and propanidid. Agents Actions 20: 219–222, 1987
Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M: Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21: 246–250, 1988
Shimomura T, Fujiwara H, Ikawa S, Kigawa J, Terakawa N: Effects of Taxol on blood cells. Lancet 352: 541–542, 1998
Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Sem Oncol 22: 16–23, 1995
Huizing MT, Keung AC, Rosing H, Van der Kuij V, Ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JR: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinumpretreated ovarian cancer patients. J Clin Oncol 11: 2127–2135, 1993
Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R: A general model for time-dissociated pharmacokineticpharmacodynamic relationship exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63: 11–25, 1998
Minami H, Sasaki Y, Saijo N, Ohtsu T, Fujii H, lgarashi T, Itoh K: Indirect-response model for the time course of leukopenia with anticancer drugs. Clin Pharmacol Ther 64: 511–521, 1998
Nygren P, Csóka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A, Lönnerholm G, Jakobsson Å, Olsen L, Kristensen J, Larsson R: The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer 71: 478–481, 1995
Csóka K, Dhar S, Fridborg H, Larsson R, Nygren P: Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer 15: 1225–1233, 1997
Fjällskog ML, Frii L, Bergh J: Paclitaxel induced cytotoxicity – the effects of cremophor EL (castor oil) on two human breast cancer cell lines with acquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 30A: 687–690, 1994
Fjällskog ML, Frii L, Bergh J: Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet 342: 873, 1993
Crispens CG, Sorenson JRJ: Treatment of reticulum cell carcinoma in SJL/J mice with Tween 80. Anticancer Res 8: 1341–1344, 1988
Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, Gundersen G: Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75: 1744–1752, 1997
Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: Cytotoxic studies of paelitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104–1109, 1993
Liebmann J, Cook JA, Mitchell JB: Cremophor EL, solvent for paclitaxel, and toxicity. Lancet 342: 1428, 1993
Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331–339, 1994
Rose WC: Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3: 311–321, 1992
Fujimoto S: Study for modifying activity of solvents on antitumor activity of paclitaxel. Gan To Kagaku Ryoho 21: 665–670, 1994(Japanese)
Adler LM, Herzog TJ, Williams S, Rader JS, Mutch DG: Analysis of exposure times and dose escalation of paclitaxel In ovarian cancer cell lines. Cancer 74: 1891–1898, 1994
Reinecke P, Corvin J, Gabbert HE, Gerharz CD: Antiproliferative effects of paclitaxel (Taxol) on human renal clear cell carcinomas in vitro. Eur J Cancer 33: 1122–1129, 1997
Engblom P, Pulkkinen JO, Rantanen V, Hirvonen H, Kulmala J, Grènman R, Grènman S: Effects of paclitaxel with or without Cremophor EL on cellular clonogenic survival and apoptosis. Eur J Cancer 35: 284–288, 1999
Gianni L, Munzone E, Capri A, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699, 1995
Gehl J, Boesgaard M, Paalke T: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7: 687–693, 1996
Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU: Prospective assessment of cardiac toxicity during a randomized Phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 24: S17–65–S17–68, 1997
Sledge GW: Doxorubicin/paclitaxel combination chemotherapy for metastatic breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 22: 123–125,1995
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC: Sequences of taxol and cisplatin: a Phase I and pharmacologic study. J Clin Oncol 9: 1692–1703, 1991
Pronk LC, Schellens JHM, Planting AST, Van den Bent MJ, Hilkens PH, Van der Burg MEL, De Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071–1079, 1997
Schellens JHM, Ma J, Bruno R, Paccaly D, Vergniol JC, Planting AST, De Boer-Dennert M, Van der Burg MEL, Stoter G, Verweij J: Pharmacokinetics of cisplatin and Taxotere (docetaxel) and PBL DNA-adduct formation of cisplatin in the sequence Taxotere/cisplatin and cisplatin/ Taxotere in a Phase I/II study in solid tumor patients (Abstract). Proc Am Soc Clin Oncol 13: 132, 1994
Ma J, Verweij J, Planting AST, De Boer-Dennert M, Van Ingen HE, Van der Burg MEL, Stoter G, Schellens JHM: Current sample handling methods for measurement of cisplatin-DNA-adducts in leukocytes in man lead to discrepant results in DNA-adduct levels and DNA-repair. Br J Cancer 71: 512–517, 1995
De Vos AI, Nooter K, Verweij J, Loos WJ, Brouwer E, DeBruijn P, Ruijgrok EJ, Van der Burg MEL, Stoter G, Sparreboom A: Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. Ann Oncol 8: 1145–1150, 1997
Zhao F-K, Chuang LF, Israel M, Chuang RY: Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. Biochem Biophys Commun 159: 1359–1367, 1989
Van der Burg MEL, De Wit R, Logmans A, Van Lent M, Stoter G, Verweij J: Phase I study of weekly cisplatin and weekly or four weekly taxol in patients with advanced ovarian cancer. Eur J Cancer 33: S245, 1997
Huizing MT, Giaccone G, van Warmerdam WC, et al: Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and sequencing study in patients with non-small cell lung cancer: A European Cancer Centre (ECC) trial. J Clin Oncol 15: 317–329, 1997
Van Warmerdam LCJ, Huizing MT, Giaccone G, Postmus PE, Ten Bokkel Huinink WW, Van Zandwijk N, Koolen MG, Helmerhorst TJ, Van der Vijgh WJ, Veenhof CH, Beijnen JH: Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24(Suppl 2): 97–104, 1997
Millward MJ, Webster LK, Rischin D, Ellis AG, Linahan BM, Maisano R, Toner GC, Stokes KH: Randomised, crossover trial to determine the effect of cremophor on the pharmacokinetics and pharmacodynamics or carboplatin-based therapy (Abstract). Ann Oncol 9(Suppl 2): 130, 1998
Kennedy MJ, Zahurak ML, Donehower R, Noe DA, Sartorius S, Chen TL, Bowling K, Rowinsky EK: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14: 783–791, 1996
Kennedy MJ, Zahurak ML, Donehower RC, Noe DA, Grochow LB, Sartorius S, Chen TL, Bowling K, Duerr M, Rowinsky EK: Sequence-dependent hematological toxicity associated with 3-hour paclitaxel/cyclophosphamide doublet. Clin Cancer Res 4: 349–356, 1998
Tolcher AW, Cowan KH, Noone MH, Denicoff AM, Kohler DR, Goldspiel BR, Barnes CS, McCabe M, Gossard MR, Zulewski J, O'shaughnessy JA: Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14: 95–102, 1996
Ibrahim NK, Ellerhorst JA, Theriault RL, Rivera E, Esmaeli B, Legha SS, Ring SE, Soon-Shiong P, Benjamin RS, Hortobagyi GN: Phase I study of Cremophor-free, proteinstabilized, nanoparticle formulation of paclitaxel (Abi-007) in solid tumors (Abstract). Proc Am Assoc Clin Oncol 18: 609F, 2000
Fumoleau P, Tubiana-Hulin M, Soulié P, Delecroix V, Sistac F, Mefti F, Soulas F, Appia F, Lebecq A, Vergniol JC, Vernillet L, Riva A: A dose finding and pharmacokinetic (PK) Phase I study of a new formulation of docetaxel (D) in advanced solid tumors (Abstract). Ann Oncol 9(Suppl 2): 101, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Zuylen, L., Verweij, J. & Sparreboom, A. Role of Formulation Vehicles in Taxane Pharmacology. Invest New Drugs 19, 125–141 (2001). https://doi.org/10.1023/A:1010618632738
Issue Date:
DOI: https://doi.org/10.1023/A:1010618632738